Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: Sins of omission or commission?

JAMA

Volumn 311, Issue 9, 2014, Pages 913-915

  Winkelmayer, Wolfgang C ^a   Turakhia, Mintu P ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ALBUMINURIA; ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; CHRONIC KIDNEY DISEASE; DEATH; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOTE; PRIORITY JOURNAL; RISK REDUCTION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY, CHRONIC; WARFARIN;

EID: 84895471880     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.1781     Document Type: Note

References (15)

1. Grams ME, Juraschek SP, Selvin E, et al. Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystatin C-based estimates. Am J Kidney Dis. 2013;62(2):253-260.
2. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399-410.
3. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors In Atrial Fibrillation) study cohorts. Circulation. 2013;127(2):224-232.
4. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
5. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage. J Am Coll Cardiol. 2011;58(4):395-401.
6. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage. Am Heart J. 2006;151(3):713-719.
7. Carrero JJ, Evans M, Szummer K, et al.Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. doi:10.1001/jama.2014.1334.
8. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-1912.
9. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019-1026. (Pubitemid 37087616)
10. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-983.
11. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010;8(10):2182-2191.
12. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20(4):912-921.
13. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2599-2604.
14. Harel Z, Sholzberg M, Shah PS, et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD [published online January 2, 2014]. J Am Soc Nephrol. 2014. doi:10.1681/ASN.2013040361.
15. Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(12):3442-3453.